TRV GP’s CytomX Therapeutics CTMX Stock Holding History

TRV GP’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,020,348	Closed	-$29M	–	5
2018 Q1	$29M	Sell	1,020,348 -2,300,000	-69%	-$65.6M	20.57%	2
2017 Q4	$70.1M	Buy	+3,320,348	New	+$68.8M	31.68%	2

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

TRV GP's CTMX Position: Q2 2018 in Review

TRV GP sold out of CytomX Therapeutics (CTMX) in Q2 2018, closing a stake of 1,020,348 shares — an estimated $29M sold.

TRV GP first reported a position in CTMX in Q4 2017 and held it in 2 quarters. The position peaked at $70.1M in Q4 2017. 142 funds tracked by Wall St. Rank hold CTMX as of Q2 2018.

TRV GP reported no remaining CytomX Therapeutics position as of Q2 2018 after selling out during the quarter.
TRV GP sold 1,020,348 CytomX Therapeutics shares in Q2 2018, an estimated $29M.
TRV GP first reported a position in CytomX Therapeutics in Q4 2017 and held it in 2 quarters.
TRV GP's CytomX Therapeutics position peaked at $70.1M in Q4 2017.
142 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2018.

Based on TRV GP's 13F filing for Q2 2018, filed 7 Aug 2018.